Abstract
Background Non-small cell lung cancer (NSCLC) histological subtypes impact treatment decisions. While pre-surgical histopathological examination is ideal, it’s not always possible. CT radiomic analysis shows promise to predict NSCLC histological subtypes.
Objective To use CT scan radiomic analysis from NSCLC-Radiomics data to predict NSCLC histological subtypes using machine learning and deep learning models.
Methods 422 CT scans from The Cancer Imaging Archive (TCIA) were analyzed. Primary neoplasms were segmented by expert radiologists. Using PyRadiomics, 2446 radiomic features were extracted; post-selection, 179 features remained. Machine learning models like logistic regression, SVM, random forest, XGBoost, LightGBM, and CatBoost were employed, alongside a deep neural network (DNN) model.
Results Random forest demonstrated the highest accuracy at 78% (95% CI: 70%-84%) and AUC-ROC at 94% (95% CI: 90%-96%). LightGBM, XGBoost, and CatBoost had AUC-ROC values of 95%, 93%, and 93% respectively. The DNN’s AUC was 94.4% (95% CI: 94.1% to 94.6%). Logistic regression had the least efficacy. For histological subtype prediction, random forest, boosting models, and DNN were superior.
Conclusions Quantitative radiomic analysis with machine learning can accurately determine NSCLC histological subtypes. Random forest, ensemble models, and DNNs show significant promise for pre-operative NSCLC classification, which can streamline therapy decisions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N/A
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Images and segmentation data are available from NSCLC-Radiomics in The Cancer Imaging Archive. Aerts HJWL, Wee L, Rios Velazquez E, Leijenaar RTH, Parmar C, Grossmann P, et al. Data From NSCLC-Radiomics [Internet]. The Cancer Imaging Archive; 2019 [cited 2023 Aug 15]. Available from: https://wiki.cancerimagingarchive.net/x/FgL1
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://www.cancerimagingarchive.net/collection/nsclc-radiomics/
https://www.cancerimagingarchive.net/collection/nsclc-radiomics/
